Opinion

Thor Halfdanarson: The risk of recurrence following resection of pNETs

Thor Halfdanarson/mayoclinic.org

Nov 1, 2024, 12:08

Thor Halfdanarson: The risk of recurrence following resection of pNETs

Thor Halfdanarson, Vice President at the North American Neuroendocrine Tumor Society, shared on X:

“This is going to be a favorite paper in the clinic when counseling patients on risk of recurrence following resection of pNETs. Node negativity and absence of lymphovascular invasion predict a very favorable outcome and low recurrence risk.”

Thor Halfdanarson

Incidence and Prognostic Implications of Lymphovascular Invasion in Node-Negative Pancreatic Neuroendocrine Tumors: Results From the US Neuroendocrine Study Group

Authors: Kota Sahara, Diamantis I. Tsilimigras, Yuki Homma, Jun Kawashima, Shishir K. Maithel, Flavio Rocha, Sharon Weber, Ryan Fields, Kamran Idrees, George A. Poultsides, Cliff Cho, Itaru Endo, Timothy M. Pawlik

Thor Halfdanarson

More posts featuring Thor Halfdanarson.

cancer Cliff Cho Diamantis I. Tsilimigras Flavio Rocha George A. Poultsides Itaru Endo Jun Kawashima Kamran Idrees Kota Sahara OncoDaily oncoology Ryan Fields Sharon Weber Shishir K. Maithel Thor Halfdanarson Timothy M. Pawlik Yuki Homma

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer